Article(id=1325224464945906326, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325224405504242054, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2026.01.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1764259200000, receivedDateStr=2025-11-28, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1793887733922, onlineDateStr=2026-11-05, pubDate=1767974400000, pubDateStr=2026-01-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793887733922, onlineIssueDateStr=2026-11-05, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793887733922, creator=13701087609, updateTime=1793887733922, updator=13701087609, issue=Issue{id=1325224405504242054, tenantId=1146029695717560320, journalId=1319690329412173987, year='2026', volume='47', issue='1', pageStart='1', pageEnd='103', issueExtLink='null', onlineDate='null', pubDate='1767974400000', pubDateStr='2026-01-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793887719751, creator='13701087609', updateTime=1793934856625, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1325422111933735069, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325224405504242054, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1325422111933735070, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325224405504242054, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=7, endPage=13, ext={EN=ArticleExt(id=1325224466543936151, articleId=1325224464945906326, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research and application progress of antibody drugs in targeted therapy for pediatric neuroblastoma, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Anti-ganglioside(GD) 2 monoclonal antibodies have been widely used in clinical practice and can significantly improve the prognosis of children with high-risk neuroblastoma(HR-NB) and refractory/relapsed neuroblastoma(R/R NB). However, some patients still experience relapse, and a few develop severe treatment-related adverse reactions. Therefore, there is an urgent need to optimize GD2-targeted antibodies or explore new therapeutic targets to increase the cure rate of NB. This paper reviewed three aspects: the clinical application progress of GD2-related antibodies, the development of GD2 antibody-drug conjugates, and the research advances in novel antibody drugs for NB,aiming to provide references for clinical practice.

, authors=Zhujun WANG, Runming JIN*, authorsList=Zhujun WANG, Runming JIN, authorCompany=null, correspAuthors=Runming JIN, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1325224466753651352, articleId=1325224464945906326, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=抗体类药物在儿童神经母细胞瘤靶向治疗中的研究与应用进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

抗神经节苷脂(ganglioside,GD)2单克隆抗体在临床中应用广泛,可显著改善高危神经母细胞瘤(high risk neuroblastoma,HR-NB)和难治/复发性NB(refractory/relapse neuroblastoma,R/R NB)患儿的预后。 尽管如此,仍有部分患儿出现复发,且其中少数发生治疗相关严重不良反应,故亟需改进GD2相关抗体或开发新靶点,以提升NB治愈率。现拟从GD2相关抗体应用进展、GD2抗体药物偶联物及NB新抗体药物研究进展这3个方面进行综述,旨在为临床提供参考。

, authors=王柱军, 金润铭*, authorsList=王柱军, 金润铭, authorCompany=null, correspAuthors=金润铭, authorNote=

王柱军,副主任医师,研究方向:儿科疾病。

, correspAuthorsNote=
金润铭,主任医师,研究方向:儿科疾病。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=vC6tpPxnwEeHm9ndKTTuhg==, magXml=WBIGvvcyp+YLLrB6AiLdQQ==, pdfUrl=null, pdf=Dyah+SoyWHb7Iz+16MAowg==, pdfFileSize=896861, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=604wxh8CklI5sA2g4NX5yQ==, mapNumber=null, fund=null)}, authors=[Author(id=1325224467043058333, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325224467118555807, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, authorId=1325224467043058333, language=EN, stringName=Zhujun WANG, firstName=Zhujun, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325224467194053280, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, authorId=1325224467043058333, language=CN, stringName=王柱军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022, bio={"content":"

王柱军,副主任医师,研究方向:儿科疾病。

"}, bioImg=null, bioContent=

王柱军,副主任医师,研究方向:儿科疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325224466954977945, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, xref=null, ext=[AuthorCompanyExt(id=1325224466963366554, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, companyId=1325224466954977945, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China), AuthorCompanyExt(id=1325224466971755163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, companyId=1325224466954977945, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022)])]), Author(id=1325224467282133666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1325224467370214052, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, authorId=1325224467282133666, language=EN, stringName=Runming JIN, firstName=Runming, middleName=null, lastName=JIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325224467454100133, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, authorId=1325224467282133666, language=CN, stringName=金润铭, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325224466954977945, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, xref=null, ext=[AuthorCompanyExt(id=1325224466963366554, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, companyId=1325224466954977945, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China), AuthorCompanyExt(id=1325224466971755163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, companyId=1325224466954977945, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022)])])], keywords=[Keyword(id=1325224467563152038, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, language=EN, orderNo=1, keyword=antibody drug), Keyword(id=1325224467638649511, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, language=EN, orderNo=2, keyword=neuroblastoma), Keyword(id=1325224467709952680, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, language=EN, orderNo=3, keyword=anti-ganglioside 2 monoclonal antibody), Keyword(id=1325224467772867241, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, language=EN, orderNo=4, keyword=targeted therapy), Keyword(id=1325224467844170410, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, language=CN, orderNo=1, keyword=抗体类药物), Keyword(id=1325224467907084971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, language=CN, orderNo=2, keyword=神经母细胞瘤), Keyword(id=1325224467969999532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, language=CN, orderNo=3, keyword=神经节苷脂2单克隆抗体), Keyword(id=1325224468037108397, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, language=CN, orderNo=4, keyword=靶向治疗)], refs=[Reference(id=1325224468246823599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=JANSKY S, SHARMA AK, KORBER V, et al. Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma[J]. Nat Genet, 2021,53(5): 683-693., articleTitle=null, refAbstract=null), Reference(id=1325224468318126768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=NI X, LI Z, LI X, et al. Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study[J]. Lancet,2022, 400(10357): 1020-1032., articleTitle=null, refAbstract=null), Reference(id=1325224468410401457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=SHARMA R, YADAV J, BHAT SA, et al. Emerging trends in neuroblastoma diagnosis, therapeutics, and research[J]. Mol Neurobiol, 2025, 62(5): 6423-6466., articleTitle=null, refAbstract=null), Reference(id=1325224468502676146, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=OESTERHELD J, FERGUSON W, KRAVEKA JM, et al.Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons[J]. J Clin Oncol,2024, 42(1): 90-102., articleTitle=null, refAbstract=null), Reference(id=1325224468565590707, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=QIAN X, ZHANG D, LI K, et al. Adverse reaction reporting for naxitamab in Chinese expanded access treatment for relapsed/refractory high-risk neuroblastoma at the children's hospital of Fudan university[J]. Drugs Real World Outcomes,2025, 12(1): 115-123., articleTitle=null, refAbstract=null), Reference(id=1325224468649476788, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=GERGES A, CANNING U. Neuroblastoma and its target therapies: a medicinal chemistry review[J]. ChemMedChem,2024, 19(9): e202300535., articleTitle=null, refAbstract=null), Reference(id=1325224468704002741, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=MOHD AB, MOHD OB, ALABDALLAT YJ, et al.Safety and efficacy of dinutuximab in the treatment of neuroblastoma: a review[J]. J Res Med Sci, 2023, 28: 71., articleTitle=null, refAbstract=null), Reference(id=1325224468766917302, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=FLAADT T, REHM J, SIMON T, et al. Long-term outcomes and quality of life of high-risk neuroblastoma patients treated with a multimodal treatment including anti-GD2 immunotherapy: a retrospective cohort study[J].Cancers(Basel), 2025, 17(1): 149., articleTitle=null, refAbstract=null), Reference(id=1325224468821443255, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=YU AL, GILMAN AL, OZKAYNAK MF, et al. Long-term follow-up of a phaseⅢ study of ch14.18(dinutuximab)+cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032[J]. Clin Cancer Res,2021, 27(8): 2179-2189., articleTitle=null, refAbstract=null), Reference(id=1325224468959855288, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=DESAI AV, GILMAN AL, OZKAYNAK MF, et al. Outcomes following GD2-directed postconsolidation therapy for neuroblastoma after cessation of random assignment on ANBL0032: a report from the children's oncology group[J].J Clin Oncol, 2022, 40(35): 4107-4118., articleTitle=null, refAbstract=null), Reference(id=1325224469014381241, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=LADENSTEIN R, POTSCHGER U, VALTEAU-COUANET D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO(dinutuximab beta) in patients with high-risk neuroblastoma(HR-NBL1/SIOPEN): a multicentre,randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(12):1617-1629., articleTitle=null, refAbstract=null), Reference(id=1325224469077295802, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=HERNADFOI M, SZABADOS M, BRUCKNER E,et al. Dinutuximab beta for the treatment of high-risk neuroblastoma: data from the hungarian pediatric oncology network[J]. J Clin Med, 2025, 14(18): 6641., articleTitle=null, refAbstract=null), Reference(id=1325224469140210363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=TROSCHKE-MEURER S, ZUMPE M, AHRENBERG PM, et al. Affinity affects the functional potency of anti-GD2 antibodies by target-mediated drug disposition[J].Cancers(Basel), 2025, 17(15): 2510., articleTitle=null, refAbstract=null), Reference(id=1325224469211513532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=LADENSTEIN R, POTSCHGER U, VALTEAU-COUANET D, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial(HR-NBL1)[J]. Cancers(Basel), 2020, 12(2): 309., articleTitle=null, refAbstract=null), Reference(id=1325224470868263613, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=YU X, KANG S, GE J, et al. A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China[J]. Bio Med Central Pediatr, 2025, 25(1): 203., articleTitle=null, refAbstract=null), Reference(id=1325224470939566782, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=WIECZOREK A, SLADOWSKA K, LODE HN. Efficacy and safety of anti-GD2 immunotherapy with dinutuximab beta in the treatment of relapsed/refractory high-risk neuroblastoma[J]. Target Oncol, 2025, 20(4): 551-568., articleTitle=null, refAbstract=null), Reference(id=1325224471015064255, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=PASQUALINI C, PROUST S, SCHLEIERMACHER G, et al. Chemo-immunotherapy rescue for high-risk neuroblastoma patients with progressive disease before high-dose chemotherapy: real-world data from the SACHA-France study[J]. Pediatr Blood Cancer, 2025, 72(12): e32080., articleTitle=null, refAbstract=null), Reference(id=1325224471086367424, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=FURMAN WL, MCCARVILLE B, SHULKIN BL, et al.Improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy:updated results of a phase Ⅱ study using hu14.18K322A[J].J Clin Oncol, 2022, 40(4): 335-344., articleTitle=null, refAbstract=null), Reference(id=1325224471157670593, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=WEI W, MODAK SI. A pharmacological and clinical profile of naxitamab for the treatment of high-risk neuroblastoma[J].Expert Rev Clin Pharmacol, 2025, 18(10): 1-13., articleTitle=null, refAbstract=null), Reference(id=1325224471224779458, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=LODE HN, HOLKO P, WIECZOREK A, et al. Dinutuximab beta versus naxitamab in the treatment of relapsed/refractory neuroblastoma in patients with stable disease, minor response or partial response and disease in bone or bone marrow: systematic review and matching-adjusted indirect comparison[J]. Cancers(Basel), 2025, 17(17): 2723., articleTitle=null, refAbstract=null), Reference(id=1325224471291888323, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=MORA J, CHAN GCF, MORGENSTERN DA, et al. The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial[J]. Nat Commun, 2025, 16(1): 1636., articleTitle=null, refAbstract=null), Reference(id=1325224471358997188, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=TROVILLION EM, MICHAEL M, BROWN L, et al.Naxitamab-combination therapy for the treatment of patients with refractory and/or relapsed high-risk neuroblastoma[J]. J Pediatr Hematol Oncol, 2025, 47(7): e349-e357., articleTitle=null, refAbstract=null), Reference(id=1325224471434494661, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=MORA J, CASTANEDA A, GOROSTEGUI M, et al.Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission[J]. Pediatr Blood Cancer, 2021, 68(10): e29121., articleTitle=null, refAbstract=null), Reference(id=1325224471514186438, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=KUSHNER BH, MODAK S, MAUGUEN A, et al. A phaseⅡ trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in first complete remission[J]. Clin Cancer Res, 2025, 31(10): 1877-1884., articleTitle=null, refAbstract=null), Reference(id=1325224471593878215, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=KUSHNER BH, BASU EM, CARDENAS FI, et al.Rapid COJEC without myeloablative therapy for high-risk neuroblastoma[J]. Int J Cancer, 2025, 157(12): 2544-2549., articleTitle=null, refAbstract=null), Reference(id=1325224471673569992, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=BALLA J, SIDDI C, SCHERMA M, et al. Antibody conjugates in neuroblastoma: a step forward in precision medicine[J]. Front Oncol, 2025, 15: 1548524., articleTitle=null, refAbstract=null), Reference(id=1325224471757456073, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=PANOSYAN WS, PANOSYAN DE. Immunoliposomes for neuroblastoma: review of the past experience and design of a novel nanoparticle[J]. Anticancer Res, 2024, 44(11): 4665-4675., articleTitle=null, refAbstract=null), Reference(id=1325224471824564938, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=KUSHWAHA AC, AYOUB M, SARKAR D, et al. Antibody functionalized targeted novel epigenetic nanotherapy for paediatric neuroblastoma[J]. Colloids Surf B Biointerfaces,2025, 257: 115137., articleTitle=null, refAbstract=null), Reference(id=1325224471895868107, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=PANOSYAN WS, PANOSYAN DE, KOSTER J, et al.Anti-GD2 immunoliposomes loaded with oxamate for neuroblastoma[J]. Pediatr Res, 2023, 94(2): 458-461., articleTitle=null, refAbstract=null), Reference(id=1325224471979754188, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHENG L, LI C, YANG X, et al. GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8[J]. Eur J Nucl Med Mol Imaging, 2025, 52(5): 1764-1777., articleTitle=null, refAbstract=null), Reference(id=1325224472046863053, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=ZADRAN SK, FACCHINELLO N, de ROSA P, et al.Systematic targeting of GD2-positive neuroblastoma tumors with a photooncolytic phage nanovector platform[J]. Adv Sci(Weinh), 2025, 12(38): e15356., articleTitle=null, refAbstract=null), Reference(id=1325224472109777614, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=K I T I D E E K, A M O N Y I N G C H A R O E N S,PREEDAGASAMZIN S, et al. Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro[J].PLoS One, 2025, 20(6): e0325389., articleTitle=null, refAbstract=null), Reference(id=1325224472181080783, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHAO P, SCHARDT J, CHIANG C I, et al. Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody design[J]. MAbs, 2025,17(1): 2570748., articleTitle=null, refAbstract=null), Reference(id=1325224472269161168, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=ROSENKRANS ZT, ERBE AK, CLEMONS NB, et al.Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors[J].bioRxiv(Preprint), 2024, doi: 10.1101/2024.05.23.595624., articleTitle=null, refAbstract=null), Reference(id=1325224472340464337, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=MIELCARSKA S, KOT A, DAWIDOWICZ M, et al. B7-H3 in cancer immunotherapy-prospects and challenges: a review of the literature[J]. Cells, 2025, 14(15): 1209., articleTitle=null, refAbstract=null), Reference(id=1325224472415961810, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=KENDSERSKY NM, LINDSAY J, KOLB EA, et al. The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models[J]. Clin Cancer Res, 2021, 27(10): 2938-2946., articleTitle=null, refAbstract=null), Reference(id=1325224472499847891, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=BRIGNOLE C, CALARCO E, BENSA V, et al. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma[J]. J Immunother Cancer, 2023, 11(9):e007174., articleTitle=null, refAbstract=null), Reference(id=1325224472566956756, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=KRAMER K, PANDIT-TASKAR N, KUSHNER BH, et al.Phase 1 study of intraventricular 131I-omburtamab targeting B7H3(CD276)-expressing CNS malignancies[J]. J Hematol Oncol, 2022, 15(1): 165., articleTitle=null, refAbstract=null), Reference(id=1325224472646648533, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=PASCUAL-PASTO G, MCINTYRE B, SHRAIM R, et al.GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies[J]. J Immunother Cancer, 2022, 10(12): e004704., articleTitle=null, refAbstract=null), Reference(id=1325224472713757398, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=OKADA R, REYES-GONZALEZ JM, RODRIGUEZ C,et al. GPC2-targeted CAR T cells engineered with NFAT-inducible membrane-tethered IL15/IL21 exhibit enhanced activity against neuroblastoma[J]. Cancer Immunol Res,2025, 13(9): 1363-1373., articleTitle=null, refAbstract=null), Reference(id=1325224472793449175, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=QUAN A, HUO M, LI D, et al. Antibody-gamma/delta T cell receptors targeting GPC2 regress neuroblastoma with low antigen density[J]. Cell Rep Med, 2025, 6(10): 102378., articleTitle=null, refAbstract=null), Reference(id=1325224472868946648, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=KOH KOK JY, GOH BH, LEE WL. Altered glycosylation of EVs in cancers: galectin-3-binding protein(LGALS3BP)[J].Discov Oncol, 2025, 16(1): 1336., articleTitle=null, refAbstract=null), Reference(id=1325224472936055513, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=CELA I, CAPONE E, PECE A, et al. LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth[J]. J Transl Med, 2025, 23(1): 431., articleTitle=null, refAbstract=null), Reference(id=1325224473015747290, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=HAMILTON AK, RADAOUI AB, TSANG M, et al. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma[J]. Cancer Cell,2024, 42(11): 1970-1982., articleTitle=null, refAbstract=null), Reference(id=1325224473074467547, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=CHANDRAN MANIMEGALAI S, KRISHNAMOORTHY SP, KALIMUTHU V, et al. An investigative study on the impact of DLK1 and NCoR1 knockdown by siRNA transfection on endometrial cancer proliferation: unveiling notch interactions[J]. Med Oncol, 2025, 42(4): 124., articleTitle=null, refAbstract=null), Reference(id=1325224473149965020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG YK, TONG JB, LUO MX, et al. Identification,experimental validation, and computational evaluation of potential ALK inhibitors through hierarchical virtual screening[J]. SAR QSAR Environ Res, 2025, 36(4): 271-285., articleTitle=null, refAbstract=null), Reference(id=1325224473225462493, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=GUERRA AD, MATKAR S, ACHOLLA C, et al. A humanized anaplastic lymphoma kinase(ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers[J]. Nat Commun, 2025, 16(1): 7578., articleTitle=null, refAbstract=null)], funds=[Fund(id=1325224468129383086, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, awardId=2024AFB644, language=CN, fundingSource=湖北省自然科学基金资助项目(2024AFB644), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1325224466954977945, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, xref=null, ext=[AuthorCompanyExt(id=1325224466963366554, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, companyId=1325224466954977945, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China), AuthorCompanyExt(id=1325224466971755163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, companyId=1325224466954977945, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2026.01.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.01.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2026.01.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2026.01.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1767974400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
抗体类药物在儿童神经母细胞瘤靶向治疗中的研究与应用进展
王柱军 , 金润铭 *
世界临床药物 | 医药专论 2026,47(1): 7-13
收起
收藏切换
世界临床药物 |医药专论 2026 , 47 (1) : 7 -13
抗体类药物在儿童神经母细胞瘤靶向治疗中的研究与应用进展
全屏
[Author(id=1325224467043058333, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325224467118555807, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, authorId=1325224467043058333, language=EN, stringName=Zhujun WANG, firstName=Zhujun, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325224467194053280, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, authorId=1325224467043058333, language=CN, stringName=王柱军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022, bio={"content":"

王柱军,副主任医师,研究方向:儿科疾病。

"}, bioImg=null, bioContent=

王柱军,副主任医师,研究方向:儿科疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325224466954977945, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, xref=null, ext=[AuthorCompanyExt(id=1325224466963366554, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, companyId=1325224466954977945, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China), AuthorCompanyExt(id=1325224466971755163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, companyId=1325224466954977945, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022)])]), Author(id=1325224467282133666, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1325224467370214052, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, authorId=1325224467282133666, language=EN, stringName=Runming JIN, firstName=Runming, middleName=null, lastName=JIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325224467454100133, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, authorId=1325224467282133666, language=CN, stringName=金润铭, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325224466954977945, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, xref=null, ext=[AuthorCompanyExt(id=1325224466963366554, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, companyId=1325224466954977945, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China), AuthorCompanyExt(id=1325224466971755163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224464945906326, companyId=1325224466954977945, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022)])])]
王柱军, 金润铭*
作者信息
  • 华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022
通讯作者:
金润铭,主任医师,研究方向:儿科疾病。
作者简介:

王柱军,副主任医师,研究方向:儿科疾病。

Research and application progress of antibody drugs in targeted therapy for pediatric neuroblastoma
Zhujun WANG, Runming JIN*
Affiliations
  • Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
出版时间: 2026-01-10 doi: 10.13683/j.wph.2026.01.002
文章导航
收藏切换

抗神经节苷脂(ganglioside,GD)2单克隆抗体在临床中应用广泛,可显著改善高危神经母细胞瘤(high risk neuroblastoma,HR-NB)和难治/复发性NB(refractory/relapse neuroblastoma,R/R NB)患儿的预后。 尽管如此,仍有部分患儿出现复发,且其中少数发生治疗相关严重不良反应,故亟需改进GD2相关抗体或开发新靶点,以提升NB治愈率。现拟从GD2相关抗体应用进展、GD2抗体药物偶联物及NB新抗体药物研究进展这3个方面进行综述,旨在为临床提供参考。

抗体类药物  /  神经母细胞瘤  /  神经节苷脂2单克隆抗体  /  靶向治疗

Anti-ganglioside(GD) 2 monoclonal antibodies have been widely used in clinical practice and can significantly improve the prognosis of children with high-risk neuroblastoma(HR-NB) and refractory/relapsed neuroblastoma(R/R NB). However, some patients still experience relapse, and a few develop severe treatment-related adverse reactions. Therefore, there is an urgent need to optimize GD2-targeted antibodies or explore new therapeutic targets to increase the cure rate of NB. This paper reviewed three aspects: the clinical application progress of GD2-related antibodies, the development of GD2 antibody-drug conjugates, and the research advances in novel antibody drugs for NB,aiming to provide references for clinical practice.

antibody drug  /  neuroblastoma  /  anti-ganglioside 2 monoclonal antibody  /  targeted therapy
王柱军, 金润铭. 抗体类药物在儿童神经母细胞瘤靶向治疗中的研究与应用进展. 世界临床药物, 2026 , 47 (1) : 7 -13 . DOI: 10.13683/j.wph.2026.01.002
Zhujun WANG, Runming JIN. Research and application progress of antibody drugs in targeted therapy for pediatric neuroblastoma[J]. World Clinical Drug, 2026 , 47 (1) : 7 -13 . DOI: 10.13683/j.wph.2026.01.002
  • 湖北省自然科学基金资助项目(2024AFB644)
参考文献 引证文献
排序方式:
[1]
JANSKY S, SHARMA AK, KORBER V, et al. Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma[J]. Nat Genet, 2021,53(5): 683-693.
[2]
NI X, LI Z, LI X, et al. Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study[J]. Lancet,2022, 400(10357): 1020-1032.
[3]
SHARMA R, YADAV J, BHAT SA, et al. Emerging trends in neuroblastoma diagnosis, therapeutics, and research[J]. Mol Neurobiol, 2025, 62(5): 6423-6466.
[4]
OESTERHELD J, FERGUSON W, KRAVEKA JM, et al.Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons[J]. J Clin Oncol,2024, 42(1): 90-102.
[5]
QIAN X, ZHANG D, LI K, et al. Adverse reaction reporting for naxitamab in Chinese expanded access treatment for relapsed/refractory high-risk neuroblastoma at the children's hospital of Fudan university[J]. Drugs Real World Outcomes,2025, 12(1): 115-123.
[6]
GERGES A, CANNING U. Neuroblastoma and its target therapies: a medicinal chemistry review[J]. ChemMedChem,2024, 19(9): e202300535.
[7]
MOHD AB, MOHD OB, ALABDALLAT YJ, et al.Safety and efficacy of dinutuximab in the treatment of neuroblastoma: a review[J]. J Res Med Sci, 2023, 28: 71.
[8]
FLAADT T, REHM J, SIMON T, et al. Long-term outcomes and quality of life of high-risk neuroblastoma patients treated with a multimodal treatment including anti-GD2 immunotherapy: a retrospective cohort study[J].Cancers(Basel), 2025, 17(1): 149.
[9]
YU AL, GILMAN AL, OZKAYNAK MF, et al. Long-term follow-up of a phaseⅢ study of ch14.18(dinutuximab)+cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032[J]. Clin Cancer Res,2021, 27(8): 2179-2189.
[10]
DESAI AV, GILMAN AL, OZKAYNAK MF, et al. Outcomes following GD2-directed postconsolidation therapy for neuroblastoma after cessation of random assignment on ANBL0032: a report from the children's oncology group[J].J Clin Oncol, 2022, 40(35): 4107-4118.
[11]
LADENSTEIN R, POTSCHGER U, VALTEAU-COUANET D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO(dinutuximab beta) in patients with high-risk neuroblastoma(HR-NBL1/SIOPEN): a multicentre,randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(12):1617-1629.
[12]
HERNADFOI M, SZABADOS M, BRUCKNER E,et al. Dinutuximab beta for the treatment of high-risk neuroblastoma: data from the hungarian pediatric oncology network[J]. J Clin Med, 2025, 14(18): 6641.
[13]
TROSCHKE-MEURER S, ZUMPE M, AHRENBERG PM, et al. Affinity affects the functional potency of anti-GD2 antibodies by target-mediated drug disposition[J].Cancers(Basel), 2025, 17(15): 2510.
[14]
LADENSTEIN R, POTSCHGER U, VALTEAU-COUANET D, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial(HR-NBL1)[J]. Cancers(Basel), 2020, 12(2): 309.
[15]
YU X, KANG S, GE J, et al. A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China[J]. Bio Med Central Pediatr, 2025, 25(1): 203.
[16]
WIECZOREK A, SLADOWSKA K, LODE HN. Efficacy and safety of anti-GD2 immunotherapy with dinutuximab beta in the treatment of relapsed/refractory high-risk neuroblastoma[J]. Target Oncol, 2025, 20(4): 551-568.
[17]
PASQUALINI C, PROUST S, SCHLEIERMACHER G, et al. Chemo-immunotherapy rescue for high-risk neuroblastoma patients with progressive disease before high-dose chemotherapy: real-world data from the SACHA-France study[J]. Pediatr Blood Cancer, 2025, 72(12): e32080.
[18]
FURMAN WL, MCCARVILLE B, SHULKIN BL, et al.Improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy:updated results of a phase Ⅱ study using hu14.18K322A[J].J Clin Oncol, 2022, 40(4): 335-344.
[19]
WEI W, MODAK SI. A pharmacological and clinical profile of naxitamab for the treatment of high-risk neuroblastoma[J].Expert Rev Clin Pharmacol, 2025, 18(10): 1-13.
[20]
LODE HN, HOLKO P, WIECZOREK A, et al. Dinutuximab beta versus naxitamab in the treatment of relapsed/refractory neuroblastoma in patients with stable disease, minor response or partial response and disease in bone or bone marrow: systematic review and matching-adjusted indirect comparison[J]. Cancers(Basel), 2025, 17(17): 2723.
[21]
MORA J, CHAN GCF, MORGENSTERN DA, et al. The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial[J]. Nat Commun, 2025, 16(1): 1636.
[22]
TROVILLION EM, MICHAEL M, BROWN L, et al.Naxitamab-combination therapy for the treatment of patients with refractory and/or relapsed high-risk neuroblastoma[J]. J Pediatr Hematol Oncol, 2025, 47(7): e349-e357.
[23]
MORA J, CASTANEDA A, GOROSTEGUI M, et al.Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission[J]. Pediatr Blood Cancer, 2021, 68(10): e29121.
[24]
KUSHNER BH, MODAK S, MAUGUEN A, et al. A phaseⅡ trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in first complete remission[J]. Clin Cancer Res, 2025, 31(10): 1877-1884.
[25]
KUSHNER BH, BASU EM, CARDENAS FI, et al.Rapid COJEC without myeloablative therapy for high-risk neuroblastoma[J]. Int J Cancer, 2025, 157(12): 2544-2549.
[26]
BALLA J, SIDDI C, SCHERMA M, et al. Antibody conjugates in neuroblastoma: a step forward in precision medicine[J]. Front Oncol, 2025, 15: 1548524.
[27]
PANOSYAN WS, PANOSYAN DE. Immunoliposomes for neuroblastoma: review of the past experience and design of a novel nanoparticle[J]. Anticancer Res, 2024, 44(11): 4665-4675.
[28]
KUSHWAHA AC, AYOUB M, SARKAR D, et al. Antibody functionalized targeted novel epigenetic nanotherapy for paediatric neuroblastoma[J]. Colloids Surf B Biointerfaces,2025, 257: 115137.
[29]
PANOSYAN WS, PANOSYAN DE, KOSTER J, et al.Anti-GD2 immunoliposomes loaded with oxamate for neuroblastoma[J]. Pediatr Res, 2023, 94(2): 458-461.
[30]
ZHENG L, LI C, YANG X, et al. GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8[J]. Eur J Nucl Med Mol Imaging, 2025, 52(5): 1764-1777.
[31]
ZADRAN SK, FACCHINELLO N, de ROSA P, et al.Systematic targeting of GD2-positive neuroblastoma tumors with a photooncolytic phage nanovector platform[J]. Adv Sci(Weinh), 2025, 12(38): e15356.
[32]
K I T I D E E K, A M O N Y I N G C H A R O E N S,PREEDAGASAMZIN S, et al. Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro[J].PLoS One, 2025, 20(6): e0325389.
[33]
ZHAO P, SCHARDT J, CHIANG C I, et al. Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody design[J]. MAbs, 2025,17(1): 2570748.
[34]
ROSENKRANS ZT, ERBE AK, CLEMONS NB, et al.Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors[J].bioRxiv(Preprint), 2024, doi: 10.1101/2024.05.23.595624.
[35]
MIELCARSKA S, KOT A, DAWIDOWICZ M, et al. B7-H3 in cancer immunotherapy-prospects and challenges: a review of the literature[J]. Cells, 2025, 14(15): 1209.
[36]
KENDSERSKY NM, LINDSAY J, KOLB EA, et al. The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models[J]. Clin Cancer Res, 2021, 27(10): 2938-2946.
[37]
BRIGNOLE C, CALARCO E, BENSA V, et al. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma[J]. J Immunother Cancer, 2023, 11(9):e007174.
[38]
KRAMER K, PANDIT-TASKAR N, KUSHNER BH, et al.Phase 1 study of intraventricular 131I-omburtamab targeting B7H3(CD276)-expressing CNS malignancies[J]. J Hematol Oncol, 2022, 15(1): 165.
[39]
PASCUAL-PASTO G, MCINTYRE B, SHRAIM R, et al.GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies[J]. J Immunother Cancer, 2022, 10(12): e004704.
[40]
OKADA R, REYES-GONZALEZ JM, RODRIGUEZ C,et al. GPC2-targeted CAR T cells engineered with NFAT-inducible membrane-tethered IL15/IL21 exhibit enhanced activity against neuroblastoma[J]. Cancer Immunol Res,2025, 13(9): 1363-1373.
[41]
QUAN A, HUO M, LI D, et al. Antibody-gamma/delta T cell receptors targeting GPC2 regress neuroblastoma with low antigen density[J]. Cell Rep Med, 2025, 6(10): 102378.
[42]
KOH KOK JY, GOH BH, LEE WL. Altered glycosylation of EVs in cancers: galectin-3-binding protein(LGALS3BP)[J].Discov Oncol, 2025, 16(1): 1336.
[43]
CELA I, CAPONE E, PECE A, et al. LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth[J]. J Transl Med, 2025, 23(1): 431.
[44]
HAMILTON AK, RADAOUI AB, TSANG M, et al. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma[J]. Cancer Cell,2024, 42(11): 1970-1982.
[45]
CHANDRAN MANIMEGALAI S, KRISHNAMOORTHY SP, KALIMUTHU V, et al. An investigative study on the impact of DLK1 and NCoR1 knockdown by siRNA transfection on endometrial cancer proliferation: unveiling notch interactions[J]. Med Oncol, 2025, 42(4): 124.
[46]
ZHANG YK, TONG JB, LUO MX, et al. Identification,experimental validation, and computational evaluation of potential ALK inhibitors through hierarchical virtual screening[J]. SAR QSAR Environ Res, 2025, 36(4): 271-285.
[47]
GUERRA AD, MATKAR S, ACHOLLA C, et al. A humanized anaplastic lymphoma kinase(ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers[J]. Nat Commun, 2025, 16(1): 7578.
2026年第47卷第1期
61
14
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2026.01.002
  • 接收时间:2025-11-28
  • 首发时间:2026-11-05
  • 出版时间:2026-01-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-11-28
基金
湖北省自然科学基金资助项目(2024AFB644)
作者信息
    华中科技大学同济医学院附属协和医院儿科,湖北 武汉 430022

通讯作者:

金润铭,主任医师,研究方向:儿科疾病。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2026.01.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏